低血糖对型糖尿病患者的影响_培训课件.pptVIP

More Hypoglycemic Events Have Been Reported by Patients Treated With a Sulfonylurea (Glyburide) vs Metformin or a Thiazolidinedione Kahn et al1 conducted A Diabetes Outcome Progression Trial (ADOPT) in patients with recently diagnosed type 2 diabetes who had not received drug treatment. The purpose was to assess the durability of glycemic control with use of a TZD (rosiglitazone; n=1456), a biguanide (metformin; n=1454), or a sulfonylurea (glyburide) (n=1441) as monotherapy for a median of 4 years.1 The results showed that hypoglycemia occurred in 9.8% of patients receiving rosiglitazone,